|
| Related disease | Agent | Effects |
|
| Hypertension | Dimethyl fumarate [66] | Downregulated the renin-angiotensin system |
| Luteolin [67] | Improved NO bioavailability, reduced blood pressure |
| Potato bioactive peptide [68] | Reduced renal damage |
| Tilapia by-product oligopeptide [70] | Reduced endothelial damage |
|
| Atherosclerosis | Epigallocatechin gallate [75] | Prevent NF-κB activation |
| Z-Ligustilide [77] | Reduced atherosclerotic plaques |
| Trans-3,5,4-trimethoxystilbene [79] | Reduced foam cell formation, atherosclerotic plaque |
|
| MI | Ulinastatin [87] | Reduced the infarct area |
| Lithium [90] | Against ventricular arrhythmias |
| PTS-HPβCD complex [91] | Improved systolic function and adverse cardiac remodeling |
| NBP [92] | Inhibited myocardial apoptosis |
| Andrographolide [93] | Attenuated cardiac fibrosis |
|
| MIRI | Atorvastatin [88] | Reduced MI area |
| Pinacidil [98] | Preserved heart function and myocardial ultrastructure |
| Dihydroquercetin [101] | Alleviated cardiac dysfunction |
| GYY4137 [102] | Reduced infarct size and cardiomyocyte apoptosis |
| α-Lipoic acid [103] | Attenuated cardiac dysfunction |
| TFCC [105] | Prevented myocardial damage |
| Arctigenin [114] | Reduced infarct area and improved arrhythmia |
| CNTF [183] | Attenuated death in myocardial cells |
|
| Heart failure/cardiac remodeling | Bardoxolone methyl [108] | Attenuated myocardial inflammation |
| NBP [115] | Improved ventricular function and prevents ventricular remodeling |
| Zingerone [116] | Suppressed cardiac hypertrophy, fibrosis, and inflammation |
| Sodium sulfide [119] | Improved left ventricular function and cardiac hypertrophy |
| DH404 [118] | Inhibited cardiac remodeling, dysfunction |
| Nitrite [120] | Ameliorated myocardial dysfunction |
|
| Cerebral hemorrhage | RS9 [130] | Decreased brain edema, neuronal damage area, and neurological deficits |
| Simvastatin [132] | Alleviated inflammatory injury, promoted neurological recovery |
| Monomethyl fumarate [133] | Improved neurological deficit |
| Isoliquiritigenin [129] | Alleviated neurological deficits, histological damage, and blood-brain barrier disruption |
| Nicotinamide mononucleotide [136] | Promoted the recovery of neurological function |
| tert-Butylhydroquinone [135] | Reduced oxidative brain damage |
| Melatonin [134] | Ameliorated early brain injury |
| Mangiferin [137] | Ameliorated their neurological deficits and brain edema |
| Sulforaphane [138] | Attenuated vasospasm, ameliorated behavioral functions disrupted |
|
| CI | Urinary kallidinogenase [140] | Reduced neurological deficit and the area of CI |
| Tissue kallikrein [141] | Improved neurological deficits and reduced the infarct size |
| Salvianolate lyophilized injection [142] | Increased the number of brain microvasculature in ipsilateral |
| Huang-Lian-Jie-Du decoction [143] | Reduced neuron structure damage, neuronal loss |
| Andrographolide [144] | Suppressed blood-brain barrier disruption, and brain infarction |
| BMMCs [145] | Improved the neurological function and reduced the infarct scope |
|
| CI/RI | Chlorogenic acid [149] | Reduced brain damage, enhanced learning, and spatial memory |
| Lyciumamide A [150] | Ameliorated oxidative damage and neuronal apoptosis |
| COM 3 [151] | Improved the neuronal mitochondrial energy metabolism |
| Schizandrin A [153] | Improved the neurological score and reduced infarct volume |
| Uric acid [154] | Decreased the infarct volume and neurological deficit |
| AFF [155] | Reduced neurologic deficits, infarct area, and histologic changes |
|
